Mark Young
Dr. Young is an experienced executive specializing in
process development and manufacturing of biopharmaceutical
products. He started his career as a process
development scientist with large international pharmaceutical
companies (Hoffmann LaRoche and Upjohn), and then
joined the biotech industry in 1985. He has served
as a Senior Vice President of three biotech companies
(Synergen, Protein Design Labs, ZymoGenetics) and
as Chief Operating Officer of Biomira. Dr.
Young received degrees at the University of Nebraska,
Columbia University, and The University of Michigan,
all in Chemical Engineering. He is currently
a consultant, specializing in bioprocess development
and manufacturing issues.
W. Todd Myers
W. Todd Myers, C.P.A., is a veteran financial executive
with significant management experience in both public
and private drug discovery/development companies. Mr.
Myers is currently a member of the Board of Advisors
of BioLaurus, Inc., a contract research organization
specializing in cutting edge molecular imaging and high
content analysis services for the biotechnology and pharmaceutical
industry. He also provides coaching and guidance
to start-up life science companies as an Entrepreneur-in-Residence
at CONNECT, a non-profit organization dedicated
to creating and sustaining the growth of innovative technology
and life science businesses in San Diego. Most
recently, Mr. Myers was the Chief Financial Officer of
SGX Pharmaceuticals, Inc., a publicly-traded biotechnology
company focused on the discovery, development and commercialization
of innovative cancer therapeutics, and was instrumental
in the sale of SGX to Eli Lilly & Company at a premium
of 119% to its then-current trading price. Prior
to SGX, as the Director of Finance at CombiChem, Inc,
a publicly-traded computational drug discovery company,
Mr. Myers managed all financial operations and was the
senior financial representative on the team responsible
for the sale of the company to DuPont Pharmaceuticals. He
was also the Chief Financial Officer of FeRx Incorporated,
a privately-held, clinical stage company dedicated to
the development of oncology products, and has held positions
with Premier Inc. and with Ernst & Young LLP. Mr.
Myers received his B.S. in Accounting from the University
of Illinois.
Tim Joy
With approximately 28 years of pharmaceutical
industry experience, Tim is a founding officer and the
current President of RMC Pharmaceutical Solutions Incorporated
(RMC). This experience extends across several pharma
organizations ranging from large global operations (American
Home Products/Wyeth-Ayerst) and mid-size development
programs (Amylin Pharmaceuticals), to early-stage/startup
companies (FeRx Incorporated and RMC). This uniquely
diverse background, includes direct experience spanning
the entire GxP (i.e. GLP, GMP and GCP) spectrum of activities
that support the pre-clinical/clinical research, CMC/product
development and commercialization of regulated drug and
device products. This background is not only an asset
in the executive team's management of RMC's corporate
development and sustained growth, but it has also been
vital in allowing Tim to serve RMC clients as a Principal
Consultant.
In the role of Principal Consultant, Tim
assists clients with creating, developing, and/or executing
and achieving their own measured solutions to both the
individual and interrelated compliance, quality and development
responsibilities of product development and commercialization
programs. Additionally, with contemporary hands-on experience
evaluating and monitoring GxP quality systems in Asia
, North America and Europe, Tim possesses a current global
perspective of precisely what is taking place to balance
and achieve the varied compliance, quality and overall
drug development objectives of numerous organizations
throughout these key regions.
Scott Rudge
Scott is a founding member of RMC
Pharmaceutical Solutions, and currently serves as
its technical leader. Scott brings 14 years experience
in the pharmaceutical industry, and an additional
seven years of academic and government sponsored
research and development in bioprocessing, to the
RMC Pharmaceutical Solutions team. Since joining
RMC Pharmaceutical Solutions in May 2004, Scott
has been involved in a wide variety of projects
for small and large biotech/pharmaceutical companies.
He has overseen and/or performed assay, equipment,
sterilization, cleaning and process validation,
formulation development, due diligence for a multimillion
dollar investment, construction of a new GMP facility
for tissue processing, and tech transfer for a major
late stage biotechnology product. Scott received
his PhD in chemical engineering from Purdue University
in 1989. In his last position, Scott served as the
Vice President of Operations at FeRx Incorporated,
overseeing manufacturing, process and product development,
analytical development, formulation, facility design,
construction and operation, and intellectual property.
He is an adjunct professor of chemical engineering
at the University of Colorado, a guest researcher
at the National Institute of Standards and Technology,
and co-author of a leading text book on bioseparations.
Scott has also worked at Amylin Pharmaceuticals
Incorporated, Synergen Incorporated, and the National
Institute of Standards and Technology. |
